Literature DB >> 26672116

Chlamydia Screening in Juvenile Corrections: Even Females Considered to Be at Low Risk Are at High Risk.

Elizabeth Torrone1, Tara Beeston2, Rosemari Ochoa2, Marjorie Richardson2, Tom Gray2, Thomas Peterman3, Kenneth A Katz4.   

Abstract

The Centers for Disease Control and Prevention recommends chlamydia screening at intake for all females in juvenile detention facilities. Identifying factors predictive of chlamydia could enable targeted screening, reducing costs while still identifying most infections. This study used demographic, arrest, and health data to identify factors associated with chlamydia among females aged 12 to 18 years entering a juvenile detention facility in San Diego during January 2009 to June 2010. The study created different screening criteria based on combinations of factors associated with infection and calculated sensitivity and proportion screened for each criterion. Overall chlamydia prevalence was 10.3% and was 4.2% among females reporting no sexual risk factors. No acceptable targeted screening approach was identified. High prevalence, even among females without risk factors, supports universal screening at intake.
© The Author(s) 2015.

Entities:  

Keywords:  chlamydia; correctional health; juvenile detention; screening

Mesh:

Year:  2016        PMID: 26672116      PMCID: PMC6891048          DOI: 10.1177/1078345815618185

Source DB:  PubMed          Journal:  J Correct Health Care        ISSN: 1078-3458


  12 in total

1.  Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy.

Authors:  J M Marrazzo; C L Celum; S D Hillis; D Fine; S DeLisle; H H Handsfield
Journal:  Sex Transm Dis       Date:  1997-03       Impact factor: 2.830

2.  Sex and age correlates of Chlamydia prevalence in adolescents and adults entering correctional facilities, 2005: implications for screening policy.

Authors:  M Riduan Joesoef; Hillard S Weinstock; Charlotte K Kent; Joan M Chow; Melina R Boudov; Farah M Parvez; Tamara Cox; Thomas Lincoln; Jamie L Miller; Maya Sternberg
Journal:  Sex Transm Dis       Date:  2009-02       Impact factor: 2.830

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Sexually transmitted diseases program performance measures: how are they performing?

Authors:  Thomas A Peterman; Daniel R Newman; Dayne E Collins; Sonal R Doshi; Stuart M Berman
Journal:  Sex Transm Dis       Date:  2011-07       Impact factor: 2.830

5.  The US Chlamydia trachomatis control program: successes, shortcomings and ideas for the future.

Authors:  David H Martin
Journal:  Sex Transm Dis       Date:  2012-12       Impact factor: 2.830

6.  Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008.

Authors:  S Deblina Datta; Elizabeth Torrone; Deanna Kruszon-Moran; Stuart Berman; Robert Johnson; Catherine L Satterwhite; John Papp; Hillard Weinstock
Journal:  Sex Transm Dis       Date:  2012-02       Impact factor: 2.830

7.  Asymptomatic sexually transmitted diseases: the case for screening.

Authors:  Thomas A Farley; Deborah A Cohen; Whitney Elkins
Journal:  Prev Med       Date:  2003-04       Impact factor: 4.018

8.  Chlamydia prevalence among women and men entering the National Job Training Program: United States, 2003-2007.

Authors:  Catherine Lindsey Satterwhite; Lin H Tian; Jimmy Braxton; Hillard Weinstock
Journal:  Sex Transm Dis       Date:  2010-02       Impact factor: 2.830

Review 9.  A systematic review and meta-analysis of the prevalence of chlamydia, gonorrhoea and syphilis in incarcerated persons.

Authors:  F G Kouyoumdjian; D Leto; S John; H Henein; S Bondy
Journal:  Int J STD AIDS       Date:  2012-04       Impact factor: 1.359

10.  Prevalence of Chlamydia trachomatis genital infection among persons aged 14-39 years--United States, 2007-2012.

Authors:  Elizabeth Torrone; John Papp; Hillard Weinstock
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-09-26       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.